OIS@AAO 2017 Videos

Piper Jaffray managing director Andrew Gitkin, head of West Coast biotech investment banking, delivers good news to attendees of OIS@AAO. Overall public markets are strong,…

Industry stalwart Jim Mazzo, global president, ophthalmology atd Zeiss, delivers his assessment of the state of innovation in ophthalmology.

Robert Dempsey, group vice president and head, global ophthalmics franchise, lays out Shire’s plans to roll out Xiidra worldwide. What are the challenges? Where will…

Jason Ehrlich, MD, PhD, the global head, clinical, of Genentech’s ophthalmology product development group, details the company’s current and future ophthalmology pipeline. He also looks…

Dirk Sauer, PhD, global development unit head of ophthalmology, lays out the next steps for Novartis’ potential AMD blockbuster. He also shares his views on…

Two principals of the alliance between the American Academy of Ophthalmology and Digisight share the genesis of the deal that will deliver insightful data to…

CEO David Parke II, MD, explains why the American Academy of Ophthalmology continues to emphasize innovation, including the creation of the valuable ISIS patient registry.

Brent Saunders, chairman, president, and CEO, says Allergan has no plans to exit ophthalmology. The pending loss of Restasis will require some cuts, but the…

The OIS Index is an ophthalmic industry stock index, launched at OIS@AAO in October 2016, as a tool to track the investment performance of publicly…

Five years out from Food and Drug Administration approval of its flagship iStent micro-invasive insert for treatment of glaucoma, Glaukos is now transitioning into a…

Ophthotech Corporation expects to start new clinical trials of its Zimura C5 inhibitor for three new indications within the next year, CEO and president Glenn…